BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37496990)

  • 1. FOXM1-regulated ZIC2 promotes the malignant phenotype of renal clear cell carcinoma by activating UBE2C/mTOR signaling pathway.
    Lv Z; Wang M; Hou H; Tang G; Xu H; Wang X; Li Y; Wang J; Liu M
    Int J Biol Sci; 2023; 19(11):3293-3306. PubMed ID: 37496990
    [No Abstract]   [Full Text] [Related]  

  • 2. Overexpressed lncRNA FTX promotes the cell viability, proliferation, migration and invasion of renal cell carcinoma via FTX/miR‑4429/UBE2C axis.
    Chen Z; Zhang M; Lu Y; Ding T; Liu Z; Liu Y; Zhou Z; Wang L
    Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35866591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway.
    Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
    Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
    Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
    [No Abstract]   [Full Text] [Related]  

  • 5. A Zic2/Runx2/NOLC1 signaling axis mediates tumor growth and metastasis in clear cell renal cell carcinoma.
    Wu CY; Li L; Chen SL; Yang X; Zhang CZ; Cao Y
    Cell Death Dis; 2021 Mar; 12(4):319. PubMed ID: 33767130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.
    Zheng Z; Zhao F; Zhu D; Han J; Chen H; Cai Y; Chen Z; Xie W
    Cell Physiol Biochem; 2018; 48(3):891-904. PubMed ID: 30032137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-182-5p inhibits the tumorigenesis of clear cell renal cell carcinoma by repressing UBE2T.
    Wu Y; Zhang C; Peng D; He S; Huang C; Qian J; Zhu W; Feng N; Gong Y; Li X; Zhou L
    Hum Cell; 2022 Mar; 35(2):542-556. PubMed ID: 35129808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIF2C promotes clear cell renal cell carcinoma progression via activating JAK2/STAT3 signaling pathway.
    Deng H; Gong X; Ji G; Li C; Cheng S
    Mol Cell Probes; 2023 Dec; 72():101938. PubMed ID: 37863123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway.
    Lu ZN; Song J; Sun TH; Sun G
    Chin Med J (Engl); 2021 Oct; 134(20):2465-2474. PubMed ID: 34620747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UBE2S promotes the development of ovarian cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate cell cycle and apoptosis.
    Zhang M; Liu Y; Yin Y; Sun Z; Wang Y; Zhang Z; Li F; Chen X
    Mol Med; 2022 Jun; 28(1):62. PubMed ID: 35658829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.
    Xu Q; Ge Q; Zhou Y; Yang B; Yang Q; Jiang S; Jiang R; Ai Z; Zhang Z; Teng Y
    EBioMedicine; 2020 Jan; 51():102609. PubMed ID: 31915116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZIC2 upregulates lncRNA SNHG12 expression to promote endometrial cancer cell proliferation and migration by activating the Notch signaling pathway.
    Cai P; Li G; Wu M; Zhang B; Bai H
    Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway.
    Liu G; Zhao X; Zhou J; Cheng X; Ye Z; Ji Z
    Cell Physiol Biochem; 2018; 48(1):371-384. PubMed ID: 30016766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LTB4R Promotes the Occurrence and Progression of Clear Cell Renal Cell Carcinoma (ccRCC) by Regulating the AKT/mTOR Signaling Pathway.
    Zhang X; Wu H; Yan X; Ma J; Chen Z
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubiquitin-specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF-κB pathway inactivation.
    Gui D; Dong Z; Peng W; Jiang W; Huang G; Liu G; Ye Z; Wang Y; Xu Z; Fu J; Luo S; Zhao Y
    Cancer Med; 2021 Jun; 10(11):3674-3688. PubMed ID: 33973730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway.
    Dong D; Mu Z; Wei N; Sun M; Wang W; Xin N; Shao Y; Zhao C
    Biomed Pharmacother; 2019 Mar; 111():917-925. PubMed ID: 30841471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.